Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418914 | 1.00 | KIF11 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| SCHEMBL14420362 | 1.00 | KIF11 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| Hydrochloric Acid SCHEMBL29213474 | 0.98 | NOS2 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| Hydrochloric Acid SCHEMBL319257 | 0.98 | NOS2 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| SCHEMBL10052913 | 0.88 | GSR (0.56) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL10052915 | 0.88 | GSR (0.56) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL16497780 | 0.88 | GSR (0.56) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Ammonia Solution, Strong SCHEMBL28728275 | 0.86 | GSR (0.54) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL17431026 | 0.85 | GSR (0.57) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL15222427 | 0.85 | GSR (0.57) | GSRGRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119061087-A | Synthesis method of (S) -2-amino-5, 5-dimethylhexanoic acid | 四川同晟生物医药有限公司 | 2024-12-03 | — | — | CN | claimed |
| US-9376694-B2 | Method for preparing optically active amino acid using cosubstrate shuttling of transaminase | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-28 | — | — | US | claimed |
| US-20150284750-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ACID USING COSUBSTRATE SHUTTLING OF TRANSAMINASE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-10-08 | — | — | US | claimed |
| CN-122094698-A | Ligands for extrahepatic delivery of siRNA | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250268854-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | VESPER BIO APS (DK) | 2025-08-28 | — | — | US | disclosed |
| CN-119061087-A | Synthesis method of (S) -2-amino-5, 5-dimethylhexanoic acid | 四川同晟生物医药有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-119061087-A | Synthesis method of (S) -2-amino-5, 5-dimethylhexanoic acid | 四川同晟生物医药有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4395776-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | Insusense ApS (DK) | 2024-07-10 | — | — | EP | disclosed |
| EP-4395776-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | Insusense ApS (DK) | 2024-07-10 | — | — | EP | disclosed |
| CN-118019533-A | 2-Amino-5, 5-dimethylhexanoic acid derivatives as sortilin modulators for the treatment of central nervous system diseases | 因苏森斯有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-118019533-A | 2-Amino-5, 5-dimethylhexanoic acid derivatives as sortilin modulators for the treatment of central nervous system diseases | 因苏森斯有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-1471511-A | Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases | ���ָ����Ӣ��ķҩ�﹫˾ | 2004-01-28 | — | — | CN | disclosed |
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACIUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030216383-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1322613-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6525052-B2 | Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1205542-A1 | L-amino acid oxidase from Rhodococcus | Degussa AG (DE) | 2002-05-15 | — | — | EP | disclosed |
| WO-2002020485-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KIF11 4802/4885GSR 310/4885GRM8 4141/4885 |
| US-20250268854-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | SORT1, NMUR2, NMUR1 | KIF11 1659/4885GSR 4825/4885GRM8 1797/4885 |
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KIF11 4802/4885GSR 310/4885GRM8 4141/4885 |
| US-20030216383-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KIF11 4802/4885GSR 310/4885GRM8 4141/4885 |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KIF11 4746/4885GSR 409/4885GRM8 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.